Myeloma Patient Registered to Run His 90th Marathon with Cancer

Don Wright didn't let his 2003 myeloma diagnosis stop him in tracks. This weekend, Don is registered to run his 90th marathon with myeloma in Washington, D.C. The 74-year old says he's managed his cancer for seven of the last twelve years with oral cancer therapies, but knows “multiple myeloma cannot be cured, so I am counting on continuing progress, research and access to the latest treatments to provide the next remission and the remission after that.”
Source: International Myeloma Foundation - Category: Hematology Source Type: news

Related Links:

Contributors : Wenzhuo Zhuang ; Bingzong LiSeries Type : Expression profiling by arrayOrganism : Homo sapiensSeveral studies demonstrate that the bromodomain inhibitor OTX015 has preclinical antitumor activity in a variety of solid tumors and hematologic cancers. However, translation of these data to molecules suitable for clinical development has not yet to be accomplished in multiple myeloma (MM). Here, we identified genes and biologic processes that underpin the antimyeloma activity of OTX015 with global transcriptomics. OTX015 exerted strong antiproliferative effect and induced cell cycle arrest in vitro. Gene expressi...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
ConclusionsAlthough an overall deficit in cancer was observed, there were notable exceptions, including newly observed excesses for AML, thyroid, testicular, and peritoneal cancers. Furthermore, endotoxin exposure may, in part, account for observed lung cancer incidence deficits. Cancer incidence patterns in the AHS suggest farm exposures ’ relevance to cancer etiology.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Systemic lupus erythematosus might be an independent risk factor for cancer. Therefore, the importance of cancer screening programs should be emphasized in systemic lupus erythematosus patients. Our study is the first large nationwide cohort study for evaluating the risk of cancer in systemic lupus erythematosus patients. PMID: 30712493 [PubMed - as supplied by publisher]
Source: Lupus - Category: Rheumatology Authors: Tags: Lupus Source Type: research
This study aimed to explore whether a correlation exists between the incidence and mortality of cancers and normalized internet search volumes on the big data platform, Baidu. We also assessed whether the distribution of people who searched for specific types of cancer differed by gender. Finally, we determined whether there were regional disparities among people who searched the Web for cancer-related information. Methods: Standard Boolean operators were used to choose search terms for each type of cancer. Spearman’s correlation analysis was used to explore correlations among monthly search index values for each can...
Source: Journal of Medical Internet Research - Category: General Medicine Authors: Source Type: research
Conclusions: Although bisphosphonate use is recommended for all patients with newly diagnosed MM receiving antineoplastic therapy, 45% of patients in the United States did not receive this guideline-recommended care. PMID: 30659126 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
ConclusionThe addition of Cy in patients with myeloma progressing on Len-dex was an inexpensive option with manageable toxicity that resulted in a clinically meaningful extension of disease control.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: January 2019Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, Volume 127, Issue 1Author(s): T. WAZZAN, W. ALMADEN, M. MONA, D. KASHTWARI, J. KATZBackgroundMedication-related osteonecrosis of the jaws (MRONJ), which causes exposed bone in the maxillofacial region, persisted for 8 weeks in a patient who was receiving a bone-modulating agent.1 Multiple myeloma (MM) is a hematologic cancer that can cause bone disease. Therefore, a potent bisphosphonate is used to control bone metastasis, but one of its adverse effects is MRONJ. Previous studies that investigated risk factors associated w...
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research
Medication-related osteonecrosis of the jaws (MRONJ), which causes exposed bone in the maxillofacial region, persisted for 8 weeks in a patient who was receiving a bone-modulating agent.1 Multiple myeloma (MM) is a hematologic cancer that can cause bone disease. Therefore, a potent bisphosphonate is used to control bone metastasis, but one of its adverse effects is MRONJ. Previous studies that investigated risk factors associated with MRONJ were done in patients with different hematologic conditions, where the underlining condition might affect the result.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Source Type: research
Abstract Immunoglobulin heavy chain (IgH) translocations are common and early oncogenic events in B cell and plasma cell malignancies including B cell non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). IgH translocations bring oncogenes into close proximity with potent enhancer elements within the IgH locus, leading to oncogene up-regulation. As IgH enhancer activity is tightly controlled by B cell lineage-specific signaling and transcriptional networks, we hypothesized that IgH enhancers are potentially druggable targets/elements. To test this, we developed a molecular imaging-based high-throughput screening...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Novel efficacious treatments with long-term tolerability are needed for transplant-ineligible, newly diagnosed multiple myeloma (NDMM) patients. This phase 2 study evaluated the safety and efficacy of all-oral ixazomib-cyclophosphamide-dexamethasone (ICd) followed by single-agent ixazomib maintenance.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Hematology | Myeloma | Oral Cancer